Bone formation;
Bone metastasis;
Immunoassay;
Osteoporosis;
Paget's disease;
N-TERMINAL PROPEPTIDE;
BONE TURNOVER MARKERS;
CONNECTIVE-TISSUE METABOLITES;
III PROCOLLAGEN;
POSTMENOPAUSAL OSTEOPOROSIS;
BREAST-CANCER;
CARBOXYTERMINAL PROPEPTIDE;
SYSTEMIC GLUCOCORTICOIDS;
OSTEOGENESIS IMPERFECTA;
TERIPARATIDE TREATMENT;
D O I:
10.1016/j.clinbiochem.2012.03.023
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
100118 [医学信息学];
100208 [临床检验诊断学];
摘要:
The aminoterminal propeptide of type I procollagen (PINP) in serum is a sensitive indicator of the synthesis of type I collagen. Four assays are available for PINP, two of them (intact PINP assays) measure the intact propeptide and the other two (total PINP assays) also detect a smaller antigen in serum. In many clinical situations, these assays give similar information, but renal insufficiency increases the concentration of the smaller antigen, influencing both the apparent concentration of PINP and assay calibration. Serum PINP is mostly affected by changes in bone metabolism. In infants and children, the concentration is much higher than in adults. Serum PINP (s-PINP) is a useful indicator of disease activity in Paget's disease of bone, in bone metastases of osteoblastic nature, and in the follow-up of treatment of osteoporosis. The IFCC and IOF recently recommended the use of s-PINP as a reference marker for bone formation in studies concerning fracture risk assessment and treatment response. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.